Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates [PDF]
BMC Infectious DiseasesBackground Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities.
Dalia Salem +5 more
doaj +4 more sources
In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways [PDF]
Case Reports in Infectious Diseases, 2018 Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed by ...
Erik Skoglund +11 more
doaj +2 more sources
Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives [PDF]
BMC MicrobiologyObjectives Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms ...
Léa Bientz +13 more
doaj +2 more sources
Ceftolozane-tazobactam versus levofloxacin in urinary tract infection [PDF]
Lancet, The, 2015 Florian Wagenlehner and colleagues (May 16, p 1949) report an industrysponsored randomised controlled trial comparing ceftolozane-tazobactam with levofl oxacin in complicated and upper urinary-tract infection. The trial results should be questioned because the design was biased against the control drug and breached the guiding principles of antibiotic ...
Tom H Boyles
exaly +12 more sources
Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies [PDF]
AntibioticsIntroduction: The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed.
Ignacio Martin-Loeches +7 more
doaj +2 more sources
Trends in Pseudomonas aeruginosa In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016–2024 [PDF]
AntibioticsObjectives: To describe annual trends in the susceptibility of clinical isolates of Pseudomonas aeruginosa from Latin America to ceftolozane/tazobactam.
Mark G. Wise +6 more
doaj +2 more sources
Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms [PDF]
BiofilmObjectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations
María Fernández-Billón +9 more
doaj +2 more sources
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections [PDF]
International Journal of Infectious Diseases, 2021 Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI).
Helio S. Sader +3 more
doaj +2 more sources
Ceftolozane/tazobactam: place in therapy [PDF]
Expert Review of Anti-Infective Therapy, 2018 Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P.
Daniele Roberto Giacobbe +2 more
exaly +3 more sources
Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia [PDF]
Dose-Response, 2020 Objectives: To assess the probability of reaching adequate pharmacokinetic/pharmacodynamics values for ceftolozane/tazobactam at different doses and degrees of renal functions in patients with Pseudomonas aeruginosa bacteremia.
Jesus Ruiz +6 more
doaj +5 more sources